Summary
This is a clinical study that has three parts. It is testing a potential new medicine
called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian,
peritoneal, and fallopian tube cancers. Part A enrolls participants with
platinum-resistant cancer, meaning their disease progressed during or within six months
of platinum-based chemotherapy. Parts B and C enroll participants with platinum-sensitive
cancer, whose disease responded and remained controlled for at least six months after
completing platinum treatment. The researchers want to find out if Sofe-M works better
than the standard treatments that doctors use now and to better understand how safe it
is. Each participant's time in the study will depend on how they respond to the
treatment.